Cargando…

SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents

Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of conce...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Valtanen, Pablo, Hope, Christopher M., Masavuli, Makutiro G., Yeow, Arthur Eng Lip, Balachandran, Harikrishnan, Mekonnen, Zelalem A., Al-Delfi, Zahraa, Abayasingam, Arunasingam, Agapiou, David, Stella, Alberto Ospina, Aggarwal, Anupriya, Bouras, George, Gummow, Jason, Ferguson, Catherine, O’Connor, Stephanie, McCartney, Erin M., Lynn, David J., Maddern, Guy, Gowans, Eric J., Reddi, Benjamin A.J., Shaw, David, Kok-Lim, Chuan, Beard, Michael R., Weiskopf, Daniela, Sette, Alessandro, Turville, Stuart G., Bull, Rowena A., Barry, Simon C., Grubor-Bauk, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110310/
https://www.ncbi.nlm.nih.gov/pubmed/35654046
http://dx.doi.org/10.1016/j.xcrm.2022.100651
_version_ 1784709075805667328
author Garcia-Valtanen, Pablo
Hope, Christopher M.
Masavuli, Makutiro G.
Yeow, Arthur Eng Lip
Balachandran, Harikrishnan
Mekonnen, Zelalem A.
Al-Delfi, Zahraa
Abayasingam, Arunasingam
Agapiou, David
Stella, Alberto Ospina
Aggarwal, Anupriya
Bouras, George
Gummow, Jason
Ferguson, Catherine
O’Connor, Stephanie
McCartney, Erin M.
Lynn, David J.
Maddern, Guy
Gowans, Eric J.
Reddi, Benjamin A.J.
Shaw, David
Kok-Lim, Chuan
Beard, Michael R.
Weiskopf, Daniela
Sette, Alessandro
Turville, Stuart G.
Bull, Rowena A.
Barry, Simon C.
Grubor-Bauk, Branka
author_facet Garcia-Valtanen, Pablo
Hope, Christopher M.
Masavuli, Makutiro G.
Yeow, Arthur Eng Lip
Balachandran, Harikrishnan
Mekonnen, Zelalem A.
Al-Delfi, Zahraa
Abayasingam, Arunasingam
Agapiou, David
Stella, Alberto Ospina
Aggarwal, Anupriya
Bouras, George
Gummow, Jason
Ferguson, Catherine
O’Connor, Stephanie
McCartney, Erin M.
Lynn, David J.
Maddern, Guy
Gowans, Eric J.
Reddi, Benjamin A.J.
Shaw, David
Kok-Lim, Chuan
Beard, Michael R.
Weiskopf, Daniela
Sette, Alessandro
Turville, Stuart G.
Bull, Rowena A.
Barry, Simon C.
Grubor-Bauk, Branka
author_sort Garcia-Valtanen, Pablo
collection PubMed
description Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs.
format Online
Article
Text
id pubmed-9110310
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91103102022-05-17 SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents Garcia-Valtanen, Pablo Hope, Christopher M. Masavuli, Makutiro G. Yeow, Arthur Eng Lip Balachandran, Harikrishnan Mekonnen, Zelalem A. Al-Delfi, Zahraa Abayasingam, Arunasingam Agapiou, David Stella, Alberto Ospina Aggarwal, Anupriya Bouras, George Gummow, Jason Ferguson, Catherine O’Connor, Stephanie McCartney, Erin M. Lynn, David J. Maddern, Guy Gowans, Eric J. Reddi, Benjamin A.J. Shaw, David Kok-Lim, Chuan Beard, Michael R. Weiskopf, Daniela Sette, Alessandro Turville, Stuart G. Bull, Rowena A. Barry, Simon C. Grubor-Bauk, Branka Cell Rep Med Article Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs. Elsevier 2022-05-17 /pmc/articles/PMC9110310/ /pubmed/35654046 http://dx.doi.org/10.1016/j.xcrm.2022.100651 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Garcia-Valtanen, Pablo
Hope, Christopher M.
Masavuli, Makutiro G.
Yeow, Arthur Eng Lip
Balachandran, Harikrishnan
Mekonnen, Zelalem A.
Al-Delfi, Zahraa
Abayasingam, Arunasingam
Agapiou, David
Stella, Alberto Ospina
Aggarwal, Anupriya
Bouras, George
Gummow, Jason
Ferguson, Catherine
O’Connor, Stephanie
McCartney, Erin M.
Lynn, David J.
Maddern, Guy
Gowans, Eric J.
Reddi, Benjamin A.J.
Shaw, David
Kok-Lim, Chuan
Beard, Michael R.
Weiskopf, Daniela
Sette, Alessandro
Turville, Stuart G.
Bull, Rowena A.
Barry, Simon C.
Grubor-Bauk, Branka
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
title SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
title_full SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
title_fullStr SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
title_full_unstemmed SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
title_short SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
title_sort sars-cov-2 omicron variant escapes neutralizing antibodies and t cell responses more efficiently than other variants in mild covid-19 convalescents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110310/
https://www.ncbi.nlm.nih.gov/pubmed/35654046
http://dx.doi.org/10.1016/j.xcrm.2022.100651
work_keys_str_mv AT garciavaltanenpablo sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT hopechristopherm sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT masavulimakutirog sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT yeowarthurenglip sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT balachandranharikrishnan sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT mekonnenzelalema sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT aldelfizahraa sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT abayasingamarunasingam sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT agapioudavid sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT stellaalbertoospina sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT aggarwalanupriya sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT bourasgeorge sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT gummowjason sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT fergusoncatherine sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT oconnorstephanie sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT mccartneyerinm sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT lynndavidj sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT maddernguy sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT gowansericj sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT reddibenjaminaj sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT shawdavid sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT koklimchuan sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT beardmichaelr sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT weiskopfdaniela sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT settealessandro sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT turvillestuartg sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT bullrowenaa sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT barrysimonc sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents
AT gruborbaukbranka sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents